https://www.optimumcomms.com/wp-content/uploads/2023/08/Bioinnovation_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 09:16:472024-03-14 09:16:47BII welcomes innovative smartRNA project to Bio Studio program
https://www.optimumcomms.com/wp-content/uploads/2023/08/Bioinnovation_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 09:16:472024-03-14 09:16:47BII welcomes innovative smartRNA project to Bio Studio program
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 09:13:302024-03-14 09:13:30Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:56:272024-03-14 09:14:41Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:09:382024-03-14 08:09:38Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
https://www.optimumcomms.com/wp-content/uploads/2024/03/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-14 08:07:482024-03-14 12:04:02Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-13 08:57:002024-03-13 08:57:00Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-12 08:40:452024-03-12 08:40:45Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ionctura_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-07 08:10:082024-03-07 08:10:08US FDA grants Orphan Drug Designation for iOnctura’s first-in-class autotaxin cancer therapy
https://www.optimumcomms.com/wp-content/uploads/2023/08/Bioinnovation_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-07 08:06:382024-03-07 08:06:38BioInnovation Institute provides financial support as six promising companies enter the Venture House program
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 11:05:252024-03-06 11:05:25Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 09:19:262024-03-08 09:21:12Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
https://www.optimumcomms.com/wp-content/uploads/2023/09/WiLD_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:44:442024-03-06 14:41:55Women in Life Science Denmark (WiLD) to host network meeting in collaboration with DANISH BIO to promote equity in the Danish life science industry
https://www.optimumcomms.com/wp-content/uploads/2023/02/ASCEneuron_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:41:032024-03-06 08:41:03Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-06 08:35:482024-03-06 08:35:48Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 16:19:392024-03-05 16:19:39Novo Holdings Venture Investments 2023 Newsletter: A record year advancing innovative therapies for patients
https://www.optimumcomms.com/wp-content/uploads/2024/03/LinkedIn-Logo.jpg
200
200
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-03-05 11:02:472024-03-05 11:02:47Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome programWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
